**Appendix no 1 – The bid form**

……………………………….. ……………………………….

………………………………. (place and date)

………………………………..

………………………………...

(name and address of the Bidder)

**The bid for the proceeding: ABM/23/2023/AZF**

**Name of the order:**

**“Determination of the pharmacokinetic profile in animal models””**

Project: "Design and clinical development of the first-in-class small-molecule drug candidate in colorectal cancer therapy, based on the immune cells stimulation to enhanced anti-cancer activity through induced protein degradation." The project co-financed from the state budget from the Medical Research Agency under the Competition no. ABM/2022/6 entitled. "Development of targeted or personalized medicine based on therapy with nucleic acids or small-molecule compounds, KWAS". Contract No. 2022/ABM/06/00001 - 00.

1. **WE SUBMIT THE BID** for fulfillment of the subject of the order and we declare to fulfill it in accordance to the conditions defined in the invitation to submit a bid no ABM/23/2023/ZF.
2. **WE OFFER** the realization of the subject of order in net price indicated in the table:

|  |  |  |  |
| --- | --- | --- | --- |
| *Note: for a validity of the bid, the net price is required for all items in the table.* ***Only one price*** *should be given for a given test; if more than one price is given for a given test - the higher price will be taken into account for the bid evaluation.*  *The price should be expressed in* ***United States Dollar (USD), Euro (EUR), Polish zloty (PLN)\**** *to two decimal places (to 1 cent rounded up).* | | | |
| **PK studies (profiling) for a single compound\*\*[[1]](#footnote-2)** | | | **Net price for a single compound** **(USD/EUR/PLN)\*** |
| 1. | Formulation tests | Solution/Suspension with the stability confirmation in a given formulation by LC/MS method | ……………………… |
| 2. | PK study in mice | Healthy mice; the Bidder must have one of these species available: CD-1, C57Bl/6, or Balb/C; including body fluids analysis method development (LC/MS/MS); routes: i.v., p.o., i.p.; Min N=3 per route/dose; price per route/dose, min. 8 time points; including the analysis of a compound concentration in plasma | ………… …………..per 1 dose/ 1 route |
| 3. | PK study in rats | Healthy rats; the Bidder must have one of these species available: SD or Wistar; including body fluids analysis method development (LC/MS/MS); routes: i.v., p.o., s.c., i.p.; Min N=3 per route/dose; Min 8 time points; price per route/dose; including the analysis of a compound concentration in plasma | ………… …………..per 1 dose/ 1 route |
| We *offer the following species of mice (please tick):*  CD-1  C57Bl/6  Balb/C  and rats1 (please tick)  SD  Wistar | | | |
| \*The Ordering party reserves the rights to choose the animal species and route of administration depending on the needs of the Ordering party. | | | |

All costs related to the realization of the order in accordance to the requirements specified in the invitation to submit a bid no ABM/23/2023/ZF are included in the price above.

1. **WE DECLARE** that:
   1. we have the permissions to perform a specific activity if the law imposes an obligation to hold it, to carry out the activity covered by the contract,
   2. During the contract execution we will have access to a group of specialists with the necessary knowledge, appropriate education and experience required for the service, including experts and consultants in the field of PK studies.
   3. We confirm that we have completed at least two projects in the field of PK studies for pharmaceutical industry partners within the last 3 years.
   4. We undertake to to humane treatment of laboratory animals used for scientific purposes in accordance with applicable legal requirements.
   5. his offer is public, except for the information contained on the pages ..................(fill in if applicable), which is a business secret within the meaning of the Anti-unfair Competition Act and as such may not be available to the public.

Being informed about responsibility for any false statement or concealment of truth, we hereby declare that the above data is true.

1. **WE CONSIDER OURSELVES** being bound with the bid for 60 days since the deadline of offers submission.
2. **ANY CORRESPONDENCE** on this proceeding should be addressed to:

First name and surname ………………………………….

Address …………………………………………………..

Phone number …………………………………………

E-mail ……………………………………………………

1. **THIS BID** we submit on \_\_\_\_\_\_\_\_\_ numbered pages and attach the following statements and documents:

1)..............................................................................................

2)…………………………………………………………………………………………

3)…………………………………………………………………………………………

4)…………………………………………………………………………………………

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

(stamp and signature of the Bidder)

1. \* - please choose one currency

   \*\* - The Bidder must have a full panel of tests in all variants listed by the Ordering Party. The Ordering party reserves the rights to choose the scope of research individually for each compound. The selection of studies depends on the results from the research work. [↑](#footnote-ref-2)